European Journal of Neurology

Article	Citations
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	213
Cognitive decline among individuals with history of mild symptomatic SARS‐CoV‐2 infection: A longitudinal prospective study nested to a population cohort	123
Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study	119
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial	118
Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus‐2 infection: A systematic review and meta‐analysis	114
Encephalitis as a neurological complication of COVID‐19: A systematic review and meta‐analysis of incidence, outcomes, and predictors	113
Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity	104
Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19	103
Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature	96
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response	96
Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series	87
Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis	86
Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency	82
European Stroke Organisation and European Academy of Neurology joint guidelines on post‐stroke cognitive impairment	76
European guideline and expert statements on the management of narcolepsy in adults and children	74
Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: A critical systematic review	73
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study	67
One‐year cognitive follow‐up of COVID‐19 hospitalized patients	66
COVID‐19 and ischemic stroke	64
Myopathy as a cause of fatigue in long‐term post‐COVID‐19 symptoms: Evidence of skeletal muscle histopathology	62
Increased risk of acute stroke among patients with severe COVID‐19: a multicenter study and meta‐analysis	60
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival	55
Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID‐19	54
Rapid onset of functional tic‐like behaviours in young adults during the COVID‐19 pandemic	53
Clinical characteristics and outcomes of thymoma‐associated myasthenia gravis	51

Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel	51
Functional motor disorders associated with other neurological diseases: Beyond the boundaries of “organic” neurology	50
Subthalamic beta band suppression reflects effective neuromodulation in chronic recordings	50
Minocycline in neurodegenerative and psychiatric diseases: An update	49
International online survey of 1048 individuals with functional neurological disorder	48
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement	48
Blood–brain barrier leakage and hemorrhagic transformation: The Reperfusion Injury in Ischemic StroKe (RISK) study	48
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study	47
Distal hereditary motor neuropathies: Mutation spectrum and genotype–phenotype correlation	46
Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection	45
Headache during SARS‐CoV‐2 infection as an early symptom associated with a more benign course of disease: a case–control study	45
Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies	45
COVID‐19 pandemic and mental distress in multiple sclerosis: Implications for clinical management	44
Cognitive sequelae of long COVID may not be permanent: A prospective study	43
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology	43
Olfactory bulb and mucosa abnormalities in persistent COVID‐19‐induced anosmia: a magnetic resonance imaging study	41
Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction	41
Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study	40
The European Academy of Neurology Brain Health Strategy: One brain, one life, one approach	40
Cross‐sectional area reference values for peripheral nerve ultrasound in adults: a systematic review and meta‐analysis—Part I: Upper extremity nerves	39
Automated speech analysis in early untreated Parkinson's disease: Relation to gender and dopaminergic transporter imaging	39
Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis	38
Relationship between COVID‐19 and movement disorders: A narrative review	37
Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS‐CoV‐2 vaccination	37
Association between neuropathy and B‐vitamins: A systematic review and meta‐analysis	37
The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis	36
Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease	36
Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID‐19 pandemic	35
Usability of the head impulse test in routine clinical practice in the emergency department to differentiate vestibular neuritis from stroke	35
Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer's disease	35
Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease	35
The European Academy of Neurology COVID‐19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID‐19	34
Acute cerebellar ataxia and myoclonus with or without opsoclonus: a para‐infectious syndrome associated with COVID‐19	34
Bilateral facial nerve palsy associated with COVID‐19 and Epstein–Barr virus co‐infection	34
Correlation between total homocysteine and cerebral small vessel disease: A Mendelian randomization study	34
Muscle involvement in SARS‐CoV‐2 infection	34
Systematic review of cases of acute myelitis in individuals with COVID‐19	34
CD8+ T‐cell predominance in autoimmune glial fibrillary acidic protein astrocytopathy	34
Cognitive frailty and falls in Chinese elderly people: a population‐based longitudinal study	34
Intracranial aneurysm wall enhancement as an indicator of instability: a systematic review and meta‐analysis	33
European Society for the Study of Tourette Syndrome 2022 criteria for clinical diagnosis of functional tic‐like behaviours: International consensus from experts in tic disorders	33
European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke	33
Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany	32
The spectrum of functional tic‐like behaviours: Data from an international registry	32
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment	32
Emerging concepts on bradykinesia in non‐parkinsonian conditions	32
Nitrous oxide‐induced myeloneuropathy	32
Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies	31
Clinic and genetic predictors in response to erenumab	31
SARS‐CoV‐2–associated Guillain‐Barre syndrome in 62 patients	31

The long‐term outcome of MOGAD: An observational national cohort study of 61 patients	31
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT stud	31
European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders	31
Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort	31
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease	30
European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies	30
Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine	30
Insomnia disorder: clinical and research challenges for the 21st century	30
Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings	30
Antiherpetic medication and incident dementia: Observational cohort studies in four countries	30
Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis	30
Healthcare costs of post‐stroke oropharyngeal dysphagia and its complications: malnutrition and respiratory infections	30
Endovascular therapy versus no endovascular therapy in patients receiving best medical management for acute isolated occlusion of the posterior cerebral artery: A systematic review andmeta‐analys	30
Neurological complications of COVID‐19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic	30
COVID‐19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR	30
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome	30
The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers	30
Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3	29
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score	28
Chronic immunoglobulin maintenance therapy in myasthenia gravis	28
Functional connectivity and topology in patients with restless legs syndrome: a case–control resting‐state functional magnetic resonance imaging study	27
Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy	27
Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis	27
Multiple sclerosis and COVID‐19: How many are at risk?	27
Endovascular treatment for basilar artery occlusion: A systematic review and meta‐analysis	27
A full year of the COVID‐19 pandemic with two infection waves and its impact on ischemic stroke patient care in Germany	27
Early shunt surgery improves survival in idiopathic normal pressure hydrocephalus	27
Risk and outcomes of COVID‐19 in patients with multiple sclerosis	27
Prognosis and risk factors associated with asymptomatic intracranial hemorrhage after endovascular treatment of large vessel occlusion stroke: a prospective multicenter cohort study	27
Clinical and radiological profile of patients with spinal muscular atrophy type 4	27
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study	27
Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy	27
Brain age as a surrogate marker for cognitive performance in multiple sclerosis	27
Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis	26
Early neurological deterioration following thrombolysis for minor stroke with isolated internal carotid artery occlusion	26
Functional neurological disorders presenting as emergencies to secondary care	26
Charcot–Marie–Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study	26
EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic	25
Joint European Academy of Neurology–European Pain Federation–Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment	25
Machine‐learning‐based outcome prediction in stroke patients with middle cerebral artery‐M1 occlusions and early thrombectomy	25
Association of short‐term exposure to ambient air pollution with mortality from ischemic and hemorrhagic stroke	25
Glymphatic dysfunction correlates with severity of small vessel disease and cognitive impairment in cerebral amyloid angiopathy	25
Protective factors for subjective cognitive decline individuals: trajectories and changes in a longitudinal study with Italian elderly	25
Cross‐sectional area reference values for peripheral nerve ultrasound in adults: A systematic review and meta‐analysis—Part II: Lower extremity nerves	24
Expanding the clinical spectrum of anti‐IgLON5 disease: A multicenter retrospective study	24
Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus	24
Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience	24
Clinical presentation and management strategies of cardiovascular autonomic dysfunction following a COVID‐19 infection – A systematic review	24
Risk factors for 2‐year mortality in patients with prolonged disorders of consciousness: An international multicentre study	24
Guillain‐Barré syndrome and COVID‐19: A 1‐year observational multicenter study	24
The core/penumbra model: implications for acute stroke treatment and patient selection in 2021	24
Distinct intra‐arterial clot localization affects tissue‐level collaterals and venous outflow profiles	23
B‐type natriuretic peptide over N‐terminal pro‐brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke	23
Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)	23
Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis	23
Meningitis due to cerebrospinal fluid leak after nasal swab testing for COVID‐19	23
Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel	23
Speech metrics, general disability, brain imaging and quality of life in multiple sclerosis	23
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis	23
Worldwide barriers to genetic testing for movement disorders	23
Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score—a prospective observational study	23
European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment	22
Short‐ and long‐term outcome and predictors in an international cohort of patients with neuro‐COVID‐19	22
Non‐alcoholic fatty liver disease and stroke: A Mendelian randomization study	22
Association between depression and motoric cognitive risk syndrome among community‐dwelling older adults in China: A 4‐year prospective cohort study	22
Is there a correlation between MOG‐associated disorder and SARS‐CoV‐2 infection?	22
Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID‐19: Case series and literature review	22
Functional connectivity changes in complex migraine aura: beyond the visual network	22
Exploratory pilot study of exogenous sustained‐release melatonin on nocturia in Parkinson's disease	22
Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish	22
Rheumatoid meningitis: A systematic review and meta‐analysis	22
Primary Sjögren syndrome‐related peripheral neuropathy: A systematic review and meta‐analysis	22
The contribution of neuropathology to multiple sclerosis research	21
The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States	21
Ultrasound‐guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients	21
Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH‐2 trial intracerebral hemorrhage population	21
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen	21
Atrial fibrosis in embolic stroke of undetermined source: A multicenter study	21
Mirror therapy for unilateral neglect after stroke: A systematic review	21
Ischemic stroke in COVID‐19 patients: Mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis	21

Delirium in acute stroke: A prospective, cross‐sectional, cohort study	21
Dural arteriovenous fistulas in cerebral venous thrombosis	21
Corneal sub‐basal whorl‐like nerve plexus: a landmark for early and follow‐up evaluation in transthyretin familial amyloid polyneuropathy	21
Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation	21
Risk of intracranial meningioma with three potent progestogens: A population‐based case–control study	21
Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without	21
Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome	21
Brain volume loss due to donanemab	21
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study	21
Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid‐19	21
Higher‐quality diet and non‐consumption of meat are associated with less self‐determined disability progression in people with multiple sclerosis: A longitudinal cohort study	21
European Academy of Neurology guidelines on the treatment of cluster headache	20
First‐line therapies in late‐onset multiple sclerosis: An Italian registry study	20
Genotype and phenotype distribution of 435 patients with Charcot–Marie–Tooth disease from central south China	20
Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis	20
Nonalcoholic fatty liver disease, serum cytokines, and dementia among rural‐dwelling older adults in China: A population‐based study	20
The severity of neuropsychiatric symptoms is higher in early‐onset than late‐onset Alzheimer’s disease	20
Headache at onset of first‐ever ischemic stroke: Clinical characteristics and predictors	20
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study	20
Safety and efficacy of mechanical thrombectomy in infective endocarditis: A matched case–control analysis from the German Stroke Registry–Endovascular Treatment	20
Effects of exergaming on hippocampal volume and brain‐derived neurotrophic factor levels in Parkinson’s disease	20
SMART syndrome: retrospective review of a rare delayed complication of radiation	19
Rapid screening for neglect following stroke: A systematic search and European Academy of Neurology recommendations	19
Neuronal intranuclear inclusion disease tremor‐dominant subtype: A mimicker of essential tremor	19
Altered ioflupane single‐photon emission computed tomography in anti‐IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature	19
Impact of the COVID‐19 pandemic and a national lockdown on hospitalizations for stroke and related 30‐day mortality in France: A nationwide observational study	19
Trends in mortality from stroke in the European Union, 1996–2015	19
Bruns' nystagmus revisited: A sign of stroke in patients with the acute vestibular syndrome	19
Sex differences in quality of life after stroke were explained by patient factors, not clinical care: evidence from the Australian Stroke Clinical Registry	19
Ultraearly thrombolysis by an anesthesiologist in a mobile stroke unit: A prospective, controlled intervention study	19
Biomarker‐based stability in limbic‐predominant amnestic mild cognitive impairment	19
Associations between gut microbiota and Parkinson disease: A bidirectional Mendelian randomization analysis	19
Functional neurological disorder in people with long COVID: A systematic review	19
Association between restless legs syndrome and peripheral neuropathy: A systematic review and meta‐analysis	19
Benefit of first‐pass complete reperfusion in thrombectomy is mediated by limited infarct growth	19
Data‐driven machine‐learning analysis of potential embolic sources in embolic stroke of undetermined source	19
A real‐world study of alemtuzumab in a cohort of Italian patients	19
Longitudinal study of clinical and neurophysiological features in essential tremor	18
Surge of Bell's Palsy in the era of COVID‐19: Systematic review	18
Blood biomarkers associated with inflammation predict poor prognosis in cerebral venous thrombosis:	18
Multimodal assessment of autonomic dysfunction in amyotrophic lateral sclerosis	18
Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin‐4 antibody: A comparative study in Chinese Han patients	18
Incidence and risk of cancer among multiple sclerosis patients: A matched population‐based cohort study	18
Status epilepticus with prominent motor symptoms clusters into distinct electroclinical phenotypes	18
A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients	18
Video quality using outpatient smartphone videos in epilepsy: Results from the OSmartViE study	18
Biological fluid levels of iron and iron‐related proteins in Parkinson’s disease: Review and meta‐analysis	18
Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis	18
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING s	18
The Unruptured Intracranial Aneurysm Treatment Score as a predictor of aneurysm growth or rupture	18
Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross‐sectional study	18
Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?	17
Diagnosis and treatment of progressive multiple sclerosis: A position paper	17
Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta‐analysis of randomized placebo‐controlled trials	17
Progression of fatigue in Parkinson’s disease – a 9‐year follow‐up	17
Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels	17
Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy	17
RFC1 repeat expansions: A recurrent cause of sensory and autonomic neuropathy with cough and ataxia	17
Gut microbiota dysbiosis in Parkinson disease: A systematic review and pooled analysis	17
Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis	17
Subarachnoid Hemorrhage Early Brain Edema Score (SEBES) as a radiographic marker of clinically relevant intracranial hypertension and unfavorable outcome after subarachnoid hemorrhage	17
COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper	17
Efficacy of transcranial direct current stimulation in people with multiple sclerosis: a review	17
Facial nerve palsy: an atypical clinical manifestation of COVID‐19 infection in a family cluster	17
Neurological and (neuro)psychological sequelae in intensive care and general ward COVID‐19 survivors	17
Diffusion magnetic resonance imaging reveals tract‐specific microstructural correlates of electrophysiological impairments in non‐myelopathic and myelopathic spinal cord compression	17
Diagnostic and prognostic utility of computed tomography perfusion imaging in posterior circulation acute ischemic stroke: A systematic review and meta‐analysis	17
Meta‐analysis of genotype and phenotype studies to confirm the predictive role of the RNF213 p.R4810K variant for moyamoya disease	17
Scoring the 10‐year risk of ambulatory disability in multiple sclerosis: the RoAD score	17
Latency of poststroke epilepsy can predict drug resistance	17
Immunomodulatory treatment in postural tachycardia syndrome: A case series	17
Circle of Willis variants and their association with outcome in patients with middle cerebral artery‐M1‐occlusion stroke	17
The mutation spectrum of Parkinson‐disease‐related genes in early‐onset Parkinson's disease in ethnic Chinese	17
Cross‐sectional area reference values for peripheral nerve ultrasound in adults: A systematic review and meta‐analysis—Part III: Cervical nerve roots and vagal nerve	17
Prevalence and genotype–phenotype correlations of GBA‐related Parkinson disease in a large Chinese cohort	17
Motor unit number estimation in adult patients with spinal muscular atrophy treated with nusinersen	16
Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis	16
Dementia increases mortality beyond effects of comorbid conditions: A national registry‐based cohort study	16
Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown	16
Factors associated with COVID‐19 in people with Parkinson’s disease: a systematic review and meta‐analysis	16
Risk factors, neuroimaging correlates and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment	16
Congenital myasthenic syndrome: Correlation between clinical features and molecular diagnosis	16
Cathepsin D as biomarker in cerebrospinal fluid of nusinersen‐treated patients with spinal muscular atrophy	16
Parkinson disease following COVID‐19: Report of six cases	16
Vestibular contributions to the Romberg test: Testing semicircular canal and otolith function	16
Impact of the COVID‐19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy	16
Pain, depression, and quality of life in adults with MOG‐antibody–associated disease	16
Enhancing the communication of functional neurological disorder diagnosis: a multidisciplinary education session	16
Corneal nerve loss is related to the severity of painful diabetic neuropathy	16
Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines	16
Magnetic resonance imaging Locus Coeruleus abnormality in amnestic Mild Cognitive Impairment is associated with future progression to dementia	16
Simulation‐based training improves process times in acute stroke care (STREAM)	16
Prognostic significance of the clinical and radiological haemorrhagic transformation subtypes in acute ischaemic stroke: A systematic review and meta‐analysis	16
Foveal changes in aquaporin‐4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive	16
Hypomyelinating leukodystrophies in adults: Clinical and genetic features	16